← 홈

Antibody · 폐암 (NSCLC)

151개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 151개
AntibodystaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSe-Hoon LeePhase 2

Olaparib+Bevacizumab to SCLC patients (Olaparib+Bevacizumab to SCLC patients)

Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAssistance Publique Hopitaux De…Phase 2

MEDI9447 (Oleclumab, Oleclumab (MEDI9447))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodyBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Tislelizumab+carboplatin)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#항체#면역항체+3
효능 ORR 21%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Rucaparib and Nivolumab)

Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 4%임상시험 1상태 ACTIVE
AntibodystaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#항체#면역항체+4
효능 ORR 41%임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#항체#면역항체+2
효능 ORR 66.7%임상시험 1상태 DISCONTINUED
AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

6 / 8 페이지

← 이전다음 →